华东医药
(000963)
| 流通市值：738.16亿 | | | 总市值：738.97亿 |
| 流通股本：17.52亿 | | | 总股本：17.54亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 32,664,143,135.68 | 21,674,928,965.21 | 10,735,787,899.82 | 41,905,707,385.91 |
| 营业收入 | 32,664,143,135.68 | 21,674,928,965.21 | 10,735,787,899.82 | 41,905,707,385.91 |
| 二、营业总成本 | 29,289,598,185.1 | 19,418,419,774.58 | 9,620,007,130.43 | 37,493,020,210.87 |
| 营业成本 | 21,715,689,459.85 | 14,327,396,132.9 | 7,206,598,136.26 | 27,988,547,185.82 |
| 税金及附加 | 172,981,938.92 | 114,585,169.4 | 57,265,200.91 | 250,638,795.43 |
| 销售费用 | 4,791,980,345.55 | 3,229,044,236.81 | 1,470,753,504.47 | 6,408,522,136.28 |
| 管理费用 | 1,090,027,991.29 | 725,296,086.8 | 355,395,350.66 | 1,397,388,188.96 |
| 研发费用 | 1,507,590,822.48 | 999,673,972.93 | 515,376,918.47 | 1,425,659,218.47 |
| 财务费用 | 11,327,627.01 | 22,424,175.74 | 14,618,019.66 | 22,264,685.91 |
| 其中:利息费用 | 86,551,703.07 | 56,147,464.39 | 25,924,507.3 | 101,203,829.32 |
| 其中:利息收入 | 72,327,993.36 | 45,613,834.96 | 27,812,843.06 | 103,997,474.21 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | -119,368,076.22 | -67,265,820.65 | -42,624,149.61 | -129,190,728.94 |
| 资产处置收益 | 1,817,243.94 | -6,201,002.36 | -14,540,990.32 | -5,463,399.18 |
| 资产减值损失(新) | - | - | - | -41,006,057.96 |
| 信用减值损失(新) | -83,959,366.71 | -83,959,366.71 | - | -112,179,415.6 |
| 其他收益 | 177,555,419.45 | 144,290,664.93 | 73,641,636.88 | 199,889,752.54 |
| 四、营业利润 | 3,350,590,171.04 | 2,243,373,665.84 | 1,132,257,266.34 | 4,324,737,325.9 |
| 加:营业外收入 | 5,639,215.91 | 4,157,614.19 | 769,095.39 | 88,009,280.04 |
| 减:营业外支出 | 93,607,836.34 | 54,367,929.24 | 28,075,417.91 | 111,232,726.47 |
| 五、利润总额 | 3,262,621,550.61 | 2,193,163,350.79 | 1,104,950,943.82 | 4,301,513,879.47 |
| 减:所得税费用 | 520,763,289.42 | 389,834,341.82 | 190,966,760.4 | 807,328,247.71 |
| 六、净利润 | 2,741,858,261.19 | 1,803,329,008.97 | 913,984,183.42 | 3,494,185,631.76 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 2,741,858,261.19 | 1,803,329,008.97 | 913,984,183.42 | 3,494,185,631.76 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 2,747,916,019.11 | 1,814,826,860.86 | 914,708,484.7 | 3,512,104,678.06 |
| 少数股东损益 | -6,057,757.92 | -11,497,851.89 | -724,301.28 | -17,919,046.3 |
| 扣除非经常损益后的净利润 | 2,693,515,147.85 | 1,761,734,255.98 | 897,337,982.42 | 3,351,680,026.72 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 1.57 | 1.03 | 0.52 | 2 |
| (二)稀释每股收益 | 1.57 | 1.03 | 0.52 | 2 |
| 八、其他综合收益 | 83,361,634.41 | 23,756,112.05 | 82,044,972.47 | -10,256,659.99 |
| 归属于母公司股东的其他综合收益 | 83,361,634.41 | 23,756,112.05 | 82,044,972.47 | -10,256,659.99 |
| 九、综合收益总额 | 2,825,219,895.6 | 1,827,085,121.02 | 996,029,155.89 | 3,483,928,971.77 |
| 归属于母公司股东的综合收益总额 | 2,831,277,653.52 | 1,838,582,972.91 | 996,753,457.17 | 3,501,848,018.07 |
| 归属于少数股东的综合收益总额 | -6,057,757.92 | -11,497,851.89 | -724,301.28 | -17,919,046.3 |
| 公告日期 | 2025-10-28 | 2025-08-20 | 2025-04-25 | 2025-04-18 |
| 审计意见(境内) | | | | 标准无保留意见 |